Vaxart has not historically implemented major traditional stock splits designed to lower share prices for retail liquidity; instead, like many small-cap biotechnology entities trading on major exchanges, its corporate discussions regarding share adjustments have historically revolved around maintaining compliance with exchange listing rules. Public companies occasionally evaluate corporate actions such as reverse stock splits if prolonged trading periods push share valuations down near minimum threshold requirements. However, Vaxart's structural capital changes are managed through standard equity offerings, warrant executions, and authorized share structure adjustments filed with regulatory authorities.